Dr. Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the approval of AVT03, a proposed biosimilar of Amgen’s AMGN Prolia (denosumab) and Xgeva (denosumab), for review.
The biologic license application (BLA) was submitted under the 351(k) pathway, which is the FDA’s biosimilar application process. AVT03 is a human monoclonal antibody developed by Alvotech.
Amgen's Prolia treats osteoporosis in postmenopausal women at high risk of fractures, especially when other treatments are ineffective. AMGN’s Xgeva helps prevent fractures, spinal cord compression and the need for bone-related surgery or radiation in patients with multiple myeloma or bone metastases from solid tumors.
Both drugs play a crucial role in Amgen’s revenue stream. In 2024, Prolia generated $2.89 billion in sales, reflecting an 8% year-over-year increase. Meanwhile, Xgeva brought in $1.51 billion, marking 5% growth compared with 2023.
Year to date, Dr. Reddy’s shares have lost 15.5% compared with the industry’s 16.4% decline.
Image Source: Zacks Investment Research
Subject to approval, RDY/ALVO’s AVT03 could significantly enhance patient access to affordable treatment options for osteoporosis and other bone-related conditions. AVT03’s approval would align with broader efforts to expand the availability of high-quality biologic medicines. Given the high cost of branded drugs, a biosimilar alternative could provide substantial financial relief to patients and healthcare systems.
Additionally, with osteoporosis affecting millions across the United States, the introduction of AVT03 could improve treatment accessibility for a large patient population in need of effective bone health therapies.
Dr. Reddy’s and Alvotech signed a license and supply agreement for AVT03 in 2024, outlining their respective roles in bringing the biosimilar to market. Per the agreement, Alvotech is responsible for the development and manufacturing of AVT03, while Dr. Reddy’s is tasked with its registration and commercialization in key markets, including the United States.
Year to date, Alvotech shares have lost 14.3% against the industry’s 7.4% growth.
Image Source: Zacks Investment Research
Contingent upon the FDA’s approval, AVT03 is expected to be available in two formulations, a single-dose prefilled syringe containing 60 mg in a 1 mL solution and a single-dose vial with 120 mg/1.7 mL (70 mg/mL) solution. RDY and ALVO have clarified that AVT03 is an investigational product that has not been approved by any regulatory authority. Its biosimilarity has also not been established or claimed.
Dr. Reddy’s and Alvotech carry a Zacks Rank #3 (Hold) each at present.
A better-ranked stock from the sector is Gilead Sciences GILD, carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 30 days, Gilead Sciences’ earnings estimate for 2025 has improved from $7.80 to $7.87 per share. During the same timeframe, the estimate for earnings per share for 2026 has improved from $8.12 to $8.27. Year to date, shares of Gilead Sciences have gained 16.1%.
GILD’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.47%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Dr. Reddy's Laboratories Ltd (RDY) : Free Stock Analysis Report
Amgen Inc. (AMGN) : Free Stock Analysis Report
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
Alvotech (ALVO) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.